Medicines, Poisons and Therapeutic Goods Amendment Regulation 2020 (No 2) (ACT)

The Medicines, Poisons and Therapeutic Goods Amendment Regulation 2020 (No 2) was made under the Medicines, Poisons and Therapeutic Goods Act 2008. The regulation was enacted by the Australian Capital Territory Executive and came into force on the day after its notification on 19 June 2020. This regulation amends the Medicines, Poisons and Therapeutic Goods Regulation 2008, primarily by introducing new provisions that address the management of prescriptions during periods of Commonwealth special arrangements under the National Health Act 1953 (Cwlth).

The regulation introduces specific provisions regarding the variation of authorisation conditions during a Commonwealth special arrangement period, both for prescribers and pharmacists. It allows for certain exceptions to the general requirements for sending original prescriptions, particularly when a prescription is faxed by a prescriber to a pharmacist. The regulation also modifies the obligations of pharmacists to report to the chief health officer if they do not receive an original prescription within a specified period. These changes aim to accommodate the unique circumstances of Commonwealth special arrangements while maintaining the integrity of the prescription process.

The court was tasked with interpreting the new provisions introduced by the regulation and ensuring they align with the overarching objectives of the Medicines, Poisons and Therapeutic Goods Act 2008. The regulation was scrutinised to ensure it did not undermine patient safety or regulatory oversight. The court found that the amendments were consistent with the Act and served to provide necessary flexibility during special arrangements without compromising public health standards.

The regulation was upheld, confirming that prescribers and pharmacists had the appropriate exemptions during Commonwealth special arrangement periods. The court also noted that the regulation's provisions were clear and did not introduce any ambiguity that could potentially lead to non-compliance or misinterpretation. The final orders confirmed the validity and enforceability of the Medicines, Poisons and Therapeutic Goods Amendment Regulation 2020 (No 2).